Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
HematologySep 1, 2026 (epub)
Clinical ResearchOncology (Medical)
Gang An, Jie Jin, Zhen Cai et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated the safety profile of talquetamab, a GPRC5D×CD3 bispecific antibody, in 41 Chinese patients with relapsed/refractory multiple myeloma. The study focused on GPRC5D-associated adverse events, which were predominantly mild and resolved in 50%-100% of cases. The median treatment duration was 7.7 months for the weekly cohort.
Key findings
- GPRC5D-associated adverse events were predominantly grade 1-2, including oral and skin AEs.
- 50%-100% of adverse events resolved by the data cutoff.
- One case required dose modification due to grade 2 weight decrease.
- Median follow-up was 16.3 months for the weekly cohort.
Why it matters
Understanding the safety profile and management of GPRC5D-associated adverse events is crucial for optimizing treatment with talquetamab in patients with relapsed/refractory multiple myeloma, potentially enhancing patient outcomes.